Previous studies have demonstrated an increased risk of breast cancer among patients with systemic sclerosis (scleroderma). To describe the clinical characteristics of 21 patients with both systemic sclerosis and breast cancer, and compare their risk factors to female scleroderma patients without breast cancer, in a population-based cohort study of South Australia. Subjects with scleroderma and breast cancer were identified from the South Australian Scleroderma Register with cross-linking to the South Australian Cancer Registry, last updated to the end of December 2005. Clinical information was obtained from standardised self-administered questionnaires and case note reviews. Odds ratios for the risk factors for breast cancer in scleroderma were determined, and clinical variables were analysed using chi square, Fisher’s exact, Mann–Whitney and t tests. At the end of December 2005 there were a total of 389 female patients with scleroderma. Of these, 21 (5.4%) had been diagnosed with breast cancer. The mean age of onset of scleroderma was 43.5 years, and the mean age of breast cancer was 60.5 years in those with scleroderma and breast cancer. The majority (71.4%) had limited scleroderma, with anti-centromere antibody being the most prevalent serological abnormality. In 16 (76%) patients the diagnosis of breast cancer occurred on an average of 22.3 years after the onset of their first scleroderma symptom. When compared to 48 controls, scleroderma patients with breast cancer were found to have a higher incidence of a positive family history of breast cancer (Fisher’s exact test, p = 0.04) and a lower incidence of hormone-replacement therapy use (Fisher’s exact test, p = 0.0026). This population-based cohort study provides evidence that the majority of patients with scleroderma and breast cancer have limited scleroderma and anti-centromere antibody. Given the increased incidence of solid tumours in systemic sclerosis, we suggest regular screening of female patients for breast cancer, especially in those with a family history.
Systemic sclerosis Breast cancer
This is a preview of subscription content, log in to check access.
Rosenthal AK, McLaughlin JK, Gridley G, Nyren O (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76:910–914PubMedCrossRefGoogle Scholar
Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21:106–111PubMedCrossRefGoogle Scholar
Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B et al. (2004) Association between systemic sclerosis and breast cancer: eight new cases and review of literature. Clin Rheumatol 23:516–522PubMedCrossRefGoogle Scholar
Scope A, Sadetzki S, Sidi Y, Barzilai A, Trau H, Kaufman B et al (2006) Breast cancer and scleroderma. Skinmed 5:18–24PubMedCrossRefGoogle Scholar
Hill CL, Nguyen AM, Roder D, Roberts-Thomson PJ (2003) Risk of cancer in patients with scleroderma: a population-based cohort study. Ann Rheum Dis 62:728–731PubMedCrossRefGoogle Scholar
Roberts-Thomson PJ, Nikoloutopoulos T, Cox S, Walker JG, Gordon TP (2003) Antinuclear antibody testing in a regional laboratory. Immunol Cell Biol 81:409–412PubMedCrossRefGoogle Scholar
Masi AT, Rodnan GP, Medsger TA, Altman RD, D’Angelo WA, Fries JF et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
Roberts-Thomson PJ, Jones M, Hakendorf P, Kencana Dharmapatni AASS, Walker JG, MacFarlane JG et al (2001) Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Int Med J 31:220–229CrossRefGoogle Scholar
Bonett A, Roder D, Milliken L (1992) The South Australian Cancer Registry: a means of assessing cancer incidence, mortality and case survival. Eur J Cancer 28A:1923–1926PubMedCrossRefGoogle Scholar
Derk CT (2007) Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol 26(10):1615–1619 Epub 2 Feb 2007PubMedCrossRefGoogle Scholar
Klippel JH, Crofford LJ, Stone JH, Weyand CM (2001) Primer on the rheumatic diseases, 12th edn. Arthritis Foundation Publishing Department, Atlanta, p 353Google Scholar
Forbes AM, Woodrow JC, Verbov JL, Graham RM (1989) Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 28:65–69PubMedCrossRefGoogle Scholar
Hasset C, Harnett P, Manolios N (2001) Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 19:197–200Google Scholar